Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Three-Period Crossover Study to Evaluate the Pharmacokinetics and Safety of Single-Dose Wafermine™ (Ketamine Sublingual Wafer) in Healthy Male and Female Subjects Under Fasting Conditions

NCT07691372 is registered in ClinicalTrials.gov with iX Biopharma Ltd. as lead sponsor.

NCT NCT07691372
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07691372 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Three-Period Crossover Study to Evaluate the Pharmacokinetics and Safety of Single-Dose Wafermine™ (Ketamine Sublingual Wafer) in Healthy Male and Female Subjects Under Fasting Conditions
Lead sponsor
iX Biopharma Ltd.
Phase
Phase 1
Overall status
Not yet recruiting
Start date
June 9, 2026
Completion date
July 17, 2026
Enrollment
14 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy adult participants